| MeSH term | MeSH ID | Detail |
|---|---|---|
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Autoimmune Diseases of the Nervous System | D020274 | 1 associated lipids |
| Migraine with Aura | D020325 | 1 associated lipids |
| Hypertensive Encephalopathy | D020343 | 1 associated lipids |
| Paraneoplastic Syndromes, Nervous System | D020361 | 1 associated lipids |
| Osteoarthritis, Knee | D020370 | 13 associated lipids |
| Sciatic Neuropathy | D020426 | 13 associated lipids |
| Peroneal Neuropathies | D020427 | 1 associated lipids |
| Brain Infarction | D020520 | 17 associated lipids |
| Stroke | D020521 | 32 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kahan BD | Cyclosporine: the base for immunosuppressive therapy--present and future. | 1993 | Transplant. Proc. | pmid:7679819 |
| Starzl TE | FK 506 versus cyclosporine. | 1993 | Transplant. Proc. | pmid:7679820 |
| Nakajima K et al. | Effects of triple therapy of cyclosporine, FK 506, and RS-61443 on allogeneic small bowel transplantation in dogs. | 1993 | Transplant. Proc. | pmid:7679821 |
| Tzakis AG et al. | Two-year experience with FK 506 in pediatric patients. | 1993 | Transplant. Proc. | pmid:7679822 |
| Gibbs JF et al. | Outcome analysis of FK 506 therapy for acute and chronic rejection. | 1993 | Transplant. Proc. | pmid:7679823 |
| Abu-Elmagd KM et al. | Monitoring and treatment of intestinal allograft rejection in humans. | 1993 | Transplant. Proc. | pmid:7680150 |
| McCauley J et al. | FK 506 in the management of nephrotic syndrome after renal transplantation. | 1993 | Transplant. Proc. | pmid:7680154 |
| Mañez R et al. | Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation. | 1993 | Transplant. Proc. | pmid:7680170 |
| Woan MC et al. | Characterization of the biopsy growth assay in monitoring cardiac transplant patients for rejection. | 1993 | Transplant. Proc. | pmid:7680171 |
| Rilo HR et al. | Effect of intraportal human islet transplantation on kidney graft survival in simultaneous kidney-islet allografts. | 1993 | Transplant. Proc. | pmid:7680172 |
| Wiesner RH et al. | Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. | 1993 | Transplant. Proc. | pmid:7682352 |
| Frank B et al. | Neurotoxicity of FK 506 in liver transplant recipients. | 1993 | Transplant. Proc. | pmid:7682355 |
| Klintmalm GB et al. | Rejection: FK 506 for rescue or maintenance. | 1993 | Transplant. Proc. | pmid:7682356 |
| Woodle ES et al. | Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. | 1993 | Transplant. Proc. | pmid:7682358 |
| Fischer S et al. | A mechanism for rotamase catalysis by the FK506 binding protein (FKBP). | 1993 | Biochemistry | pmid:7505615 |
| Woodle ES et al. | FK 506 rescue therapy: early conversion improves efficacy. | 1993 | Transplant. Proc. | pmid:7682359 |
| Thomson AW et al. | ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. | 1993 | Autoimmunity | pmid:7505632 |
| Woodle ES et al. | FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease. | 1993 | Transplant. Proc. | pmid:7682360 |
| López-Gil JA and GarcÃa Sáiz M | [FK506: an immunosuppressor for the '90's?]. | 1993 | Med Clin (Barc) | pmid:7505871 |
| Kagayama A et al. | Oral absorption of FK506 in rats. | 1993 | Pharm. Res. | pmid:7505939 |
| Kim YI et al. | Augmentation of hepatocyte proliferation by immunosuppressant pretherapy is associated with up-regulation of malondialdehyde production. | 1993 | Res Exp Med (Berl) | pmid:7506444 |
| Nakamura T et al. | Protein phosphatase type 2B (calcineurin)-mediated, FK506-sensitive regulation of intracellular ions in yeast is an important determinant for adaptation to high salt stress conditions. | 1993 | EMBO J. | pmid:7693452 |
| Higa A et al. | Attenuation of epithelial injury in acute experimental colitis by immunomodulators. | 1993 | Eur. J. Pharmacol. | pmid:7693488 |
| Schmitt J et al. | Cloning and expression of a mouse cDNA encoding p59, an immunophilin that associates with the glucocorticoid receptor. | 1993 | Gene | pmid:7693550 |
| Nishikawa T et al. | Kinetic analysis of molecular interconversion of immunosuppressant FK506 by high-performance liquid chromatography. | 1993 | Pharm. Res. | pmid:7508108 |
| Shafiee A et al. | Enzymatic synthesis and immunosuppressive activity of novel desmethylated immunomycins (ascomycins). | 1993 | J. Antibiot. | pmid:7693638 |
| Keicho N et al. | Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. | 1993 | J. Antibiot. | pmid:7693639 |
| Iwasaki K et al. | Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. | 1993 | Res. Commun. Chem. Pathol. Pharmacol. | pmid:7508138 |
| Takada K et al. | Distribution characteristics of immunosuppressants FK506 and cyclosporin A in the blood compartment. | 1993 | Biopharm Drug Dispos | pmid:7508273 |
| Soldin SJ et al. | Immunophilin receptors for immunosuppressive drugs. | 1993 | Ther Drug Monit | pmid:7510077 |
| McMichael J et al. | Computer-guided concentration-controlled trials in autoimmune disorders. | 1993 | Ther Drug Monit | pmid:7510078 |
| Francavilla A et al. | Hepatic regeneration and growth factors. | 1993 | J Surg Oncol Suppl | pmid:7684910 |
| Lemster B et al. | Blood lymphocytes of autoimmune disease patients receiving FK506 exhibit normal ex vivo cytokine gene expression and proliferative responses. | 1993 | Immunol. Lett. | pmid:7510265 |
| Connelly PR et al. | Probing hydration contributions to the thermodynamics of ligand binding by proteins. Enthalpy and heat capacity changes of tacrolimus and rapamycin binding to FK506 binding protein in D2O and H2O. | 1993 | Biochemistry | pmid:7684925 |
| Parent SA et al. | Calcineurin-dependent growth of an FK506- and CsA-hypersensitive mutant of Saccharomyces cerevisiae. | 1993 | J. Gen. Microbiol. | pmid:7510323 |
| Wallemacq PE et al. | Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours. | 1993 | Clin. Chem. | pmid:7684956 |
| Mochizuki M et al. | A clinical trial of FK506 in refractory uveitis. | 1993 | Am. J. Ophthalmol. | pmid:7685147 |
| Fenton M and Kay JE | Thapsigargin activates lymphocytes via a different pathway from ionomycin. | 1993 | Biochem. Soc. Trans. | pmid:7510649 |
| Henke W and Jung K | Comparison of the effects of the immunosuppressive agents FK 506 and cyclosporin A on rat kidney mitochondria. | 1993 | Biochem. Pharmacol. | pmid:7690566 |
| Koga T et al. | Pulmonary infiltrates recovered by FK506 in a patient with Behçet's disease. | 1993 | Chest | pmid:7686837 |
| Nishi M et al. | Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. | 1993 | Invest. Ophthalmol. Vis. Sci. | pmid:7686893 |
| Nishizawa S et al. | Therapeutic effect of a new immunosuppressant, FK-506, on vasospasm after subarachnoid hemorrhage. | 1993 | Neurosurgery | pmid:7687044 |
| Warty V et al. | FK506 measurement: comparison of different analytical methods. | 1993 | Ther Drug Monit | pmid:7687389 |
| Iwata H et al. | Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. | 1993 | Transplantation | pmid:7687396 |
| Groth CG et al. | New immunosuppressive drugs in transplantation. | 1993 | Transplant. Proc. | pmid:7689274 |
| McMaster P and Buist L | FK 506 in transplantation. | 1993 | Transplant. Proc. | pmid:7689275 |
| Jost U et al. | FK 506 treatment of intractable rejection after liver transplantation. | 1993 | Transplant. Proc. | pmid:7689276 |
| Winkler M et al. | Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation. | 1993 | Transplant. Proc. | pmid:7689277 |
| Viebahn R et al. | Simulation of hypoxic and preservation injury in human hepatocyte cultures: influence of FK 506 and cyclosporine. | 1993 | Transplant. Proc. | pmid:7689278 |
| Lee KK et al. | Successful treatment of ongoing intestinal allograft rejection permits recovery of graft structure and function. | 1993 | Am. J. Surg. | pmid:7678188 |